These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 8160476)

  • 21. [Role of oxidation of lipoproteins in the pathogenesis of atherosclerosis].
    Picard S
    Pathol Biol (Paris); 1996 Jan; 44(1):46-50. PubMed ID: 8734300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low density lipoprotein oxidation and atherogenesis: from experimental models to clinical studies.
    Napoli C
    G Ital Cardiol; 1997 Dec; 27(12):1302-14. PubMed ID: 9470066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.
    Chapman MJ; Guérin M; Bruckert E
    Eur Heart J; 1998 Feb; 19 Suppl A():A24-30. PubMed ID: 9519339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cholesterol oxidation, macrophage foam cells and atherosclerosis: importance of antioxidants and paraoxonase].
    Aviram M
    Harefuah; 1999 Apr; 136(8):620-6. PubMed ID: 10955072
    [No Abstract]   [Full Text] [Related]  

  • 25. The role of dietary oxidized cholesterol and oxidized fatty acids in the development of atherosclerosis.
    Staprans I; Pan XM; Rapp JH; Feingold KR
    Mol Nutr Food Res; 2005 Nov; 49(11):1075-82. PubMed ID: 16270280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxidation of low density lipoprotein, phospholipid alterations and vascular function.
    Huang M; Leung SW; Teoh H; Man RY
    Chin Med J (Engl); 1999 Sep; 112(9):775-9. PubMed ID: 11717943
    [No Abstract]   [Full Text] [Related]  

  • 27. Physiological aspects of low-density lipoprotein oxidation.
    Thomas MJ
    Curr Opin Lipidol; 2000 Jun; 11(3):297-301. PubMed ID: 10882346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Atherosclerosis partly due to local vasculitis].
    van Deventer SJ; Kastelein JJ; ten Cate JW
    Ned Tijdschr Geneeskd; 1994 Feb; 138(9):443-8. PubMed ID: 8133943
    [No Abstract]   [Full Text] [Related]  

  • 29. The role of oxidized LDL in the atherogenic process.
    Witztum JL
    J Atheroscler Thromb; 1994; 1(2):71-5. PubMed ID: 9222872
    [No Abstract]   [Full Text] [Related]  

  • 30. Low-density lipoprotein particle composition: what is the contribution to atherogenicity?
    Rudel LL; Kesäniemi YA
    Curr Opin Lipidol; 2000 Jun; 11(3):227-8. PubMed ID: 10882336
    [No Abstract]   [Full Text] [Related]  

  • 31. The role of oxidized LDL in atherosclerosis.
    Witztum JL
    Adv Exp Med Biol; 1991; 285():353-65. PubMed ID: 1858567
    [No Abstract]   [Full Text] [Related]  

  • 32. Lipids and the pathogenesis of kidney disease.
    Moorhead JF
    Am J Kidney Dis; 1991 May; 17(5 Suppl 1):65-70. PubMed ID: 2024677
    [No Abstract]   [Full Text] [Related]  

  • 33. Atherosclerosis: cell biology and lipoproteins.
    Lester LB; Duell PB
    Curr Opin Lipidol; 1995 Dec; 6(6):U165-71. PubMed ID: 8750259
    [No Abstract]   [Full Text] [Related]  

  • 34. Complement activation by oxidatively modified low-density lipoproteins.
    Demacker PN
    Eur J Clin Invest; 1999 Oct; 29(10):811-3. PubMed ID: 10583420
    [No Abstract]   [Full Text] [Related]  

  • 35. Formation, metabolism and physiologic effects of oxidatively modified low density lipoprotein. Overview.
    Shireman R
    J Nutr; 1996 Apr; 126(4 Suppl):1049S-52S. PubMed ID: 8642430
    [No Abstract]   [Full Text] [Related]  

  • 36. Biochemical, structural, and functional properties of oxidized low-density lipoprotein.
    Esterbauer H; Dieber-Rotheneder M; Waeg G; Striegl G; Jürgens G
    Chem Res Toxicol; 1990; 3(2):77-92. PubMed ID: 2130945
    [No Abstract]   [Full Text] [Related]  

  • 37. Novel atherogenic, oxidative modification of low-density lipoprotein.
    Parthasarathy S
    Diabetes Metab Rev; 1991 Sep; 7(3):163-71. PubMed ID: 1817001
    [No Abstract]   [Full Text] [Related]  

  • 38. Is low-density lipoprotein hormone-like?
    Jacobs M; Bruckdorfer KR
    Trends Pharmacol Sci; 1988 Jul; 9(7):235-6. PubMed ID: 3247677
    [No Abstract]   [Full Text] [Related]  

  • 39. LDL particle size: an important drug target?
    Rajman I; Eacho PI; Chowienczyk PJ; Ritter JM
    Br J Clin Pharmacol; 1999 Aug; 48(2):125-33. PubMed ID: 10417486
    [No Abstract]   [Full Text] [Related]  

  • 40. Anti-atherogenic action of oestrogen.
    Umeki S
    Lancet; 1994 Mar; 343(8897):598. PubMed ID: 7906344
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.